Equities research analysts at Royal Bank Of Canada started coverage on shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) in a report released on Thursday, The Fly reports. The brokerage set a “sector perform” rating on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on BCRX. Piper Jaffray Companies reissued an “overweight” rating and set a $15.00 price objective (up from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th. Noble Financial reissued a “buy” rating on shares of BioCryst Pharmaceuticals in a research note on Tuesday, August 8th. ValuEngine raised shares of BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, August 10th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $9.13.

BioCryst Pharmaceuticals (NASDAQ BCRX) traded down 3.73% on Thursday, reaching $5.16. The company’s stock had a trading volume of 2,874,133 shares. The firm has a 50 day moving average price of $4.86 and a 200 day moving average price of $6.09. BioCryst Pharmaceuticals has a 52 week low of $3.75 and a 52 week high of $9.25. The stock’s market capitalization is $415.01 million.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). BioCryst Pharmaceuticals had a negative net margin of 160.97% and a negative return on equity of 276.62%. The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $5.79 million. During the same period in the prior year, the firm earned ($0.22) earnings per share. The firm’s quarterly revenue was down 35.4% on a year-over-year basis. On average, equities analysts anticipate that BioCryst Pharmaceuticals will post ($0.75) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/14/biocryst-pharmaceuticals-inc-bcrx-receives-new-coverage-from-analysts-at-royal-bank-of-canada.html.

A number of institutional investors have recently made changes to their positions in BCRX. Legal & General Group Plc boosted its position in BioCryst Pharmaceuticals by 4.9% during the 2nd quarter. Legal & General Group Plc now owns 18,346 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 860 shares during the period. Principal Financial Group Inc. boosted its position in BioCryst Pharmaceuticals by 0.3% during the 1st quarter. Principal Financial Group Inc. now owns 13,250 shares of the biotechnology company’s stock worth $111,000 after purchasing an additional 45 shares during the period. Fox Run Management L.L.C. purchased a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth $126,000. Janney Montgomery Scott LLC boosted its position in BioCryst Pharmaceuticals by 4.7% during the 2nd quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 1,500 shares during the period. Finally, Pacad Investment Ltd. purchased a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth $196,000. 86.23% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

The Fly

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.